지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.7
- 수록면
- 530 - 542 (13page)
- DOI
- 10.14366/usg.21172
이용수
초록· 키워드
오류제보하기
Purpose: The aim of this study was to investigate the optimal washout criteria of perfluorobutane-enhanced ultrasonography (PFB-US) for the diagnosis of hepatocellular carcinoma (HCC) in high-risk individuals.Methods: Participants at risk of HCC with treatment-naïve solid hepatic observations (≥1 cm) who underwent PFB-US from March 2019 to September 2020 were prospectively recruited. Arterial phase hyperenhancement (APHE), washout time, and washout degree were evaluated. The diagnosis of HCC was made by non-rim APHE with late and mild washout. The per-lesion diagnostic performance for diagnosing HCC using different cutoffs for late washout (50, 55, 60, 65, and 70 seconds postcontrast) and the different time windows for determining washout (until 2, 3, 4, 5, 6, 7, 8, 9, and 10 minutes postcontrast) were compared using the McNemar test.Results: In total, 101 participants with 113 observations (mean size, 33.5±2.8 mm; HCCs [n=82], non-HCC malignancies [n=16], benign [n=15]) were evaluated. Non-rim APHE was observed in 86.6% (71/82) of HCCs. As the cutoff time for late washout increased, the specificity increased to 100% (95% confidence interval [CI], 88.8% to 100%) at the 60-second cutoff with 62.2% sensitivity (95% CI, 50.8% to 72.7%). When the time window for determining washout became wider, the sensitivity and accuracy increased until 6 minutes, with 100% specificity at all times. Conclusion: Determining washout within 6 minutes after contrast injection with a 60-second cutoff for late washout showed the highest sensitivity without losing specificity for diagnosing HCC using PFB-US in individuals at high risk.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Contrast-enhanced ultrasound approach to the diagnosis of focal liver lesions: the importance of washout
ULTRASONOGRAPHY
2019 .01
-
Clinical Outcome of Fine Needle Aspiration Cytology and Washout Thyroglobulin in Suspicious Lymph Nodes in Differentiated Thyroid Carcinoma: Discordant Results in Real-World Practice
International Journal of Thyroidology
2021 .01
-
The Diagnostic Accuracy of Washout Thyroglobulin Cutoff Value in Patients with Negative Fine-needle Aspiration Cytology
대한외과학회 학술대회 초록집
2022 .11
-
Contrast-enhanced ultrasound imaging features and clinical characteristics of combined hepatocellular cholangiocarcinoma: comparison with hepatocellular carcinoma and cholangiocarcinoma
ULTRASONOGRAPHY
2020 .01
-
Contrast-enhanced ultrasound Liver Imaging Reporting and Data System category M: a systematic review and meta-analysis
ULTRASONOGRAPHY
2022 .01
-
Contrast-enhanced Ultrasonography: The Third Modality for Differentiation of Liver Mass
Journal of Liver Cancer
2019 .01
-
Evaluation of Liver Metastases Using Contrast-Enhanced Ultrasound: Enhancement Patterns and Influencing Factors
Gut and Liver
2016 .01
-
Metabolome analysis of zebrafish embryo exposed to perfluorobutane sulfonate
환경독성보건학회 심포지엄 및 학술대회
2022 .05
-
Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?
Clinical and Molecular Hepatology
2020 .01
-
The clinical management of hepatocellular carcinoma in China: Progress and challenges
Clinical and Molecular Hepatology
2023 .04
-
Role of Surgery in Stage IV Hepatocellular Carcinoma (HCC)
대한임상종양학회 학술대회지
2015 .02
-
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
Clinical and Molecular Hepatology
2023 .01
-
Ultrasound findings in peliosis hepatis
ULTRASONOGRAPHY
2021 .10
-
Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand?
ULTRASONOGRAPHY
2019 .01
-
Systemic therapy in advanced hepatocellular carcinoma
Clinical and Molecular Hepatology
2023 .04
-
The development of alcohol-associated hepatocellular carcinoma mouse model
한국실험동물학회 학술발표대회 논문집
2022 .07
-
Hepatitis C Virus Associated Hepatocellular Carcinoma Risk
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
How long should physicians follow up with patients after curative treatment for hepatocellular carcinoma?
Clinical and Molecular Hepatology
2020 .01
-
Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma
Clinical and Molecular Hepatology
2023 .04
-
Surveillance for hepatocellular carcinoma: It is time to move forward
Clinical and Molecular Hepatology
2022 .10
이 논문의 저자 정보
최근 본 자료
댓글(0)
0